Citeline logo with a tagline underneath that reads a Norstella company.
Contact Us
Report
February 24, 2026

Q4 2025 Gene, Cell, & RNA Therapy Landscape Report

The report provides a data‑driven snapshot of a sector in transition. Covering global pipeline activity, regulatory progress, and investment trends, the report highlights where innovation is advancing—and where portfolios are becoming more selective.

Inside the report
  • Three new gene and RNA therapy approvals in Q4 2025
  • A modest pipeline contraction driven primarily by fewer preclinical programs
  • A sharp rebound in start‑up financing, signaling renewed investor confidence

Citeline may contact you about relevant products, services, and content. To opt out of these communications or to manage what you receive, please visit our Preference Center.

Your information will be used in accordance with our Privacy notice.

サイトラインより、関連する製品・サービス・コンテンツに関する情報をお届けする場合があります。配信停止や受信内容の管理をご希望の場合は、プリファレンスセンターをご利用ください。

ご提供いただいた情報は、当社のプライバシー通知に基づき適切に取り扱います。